Monoclonal antibody directed against CD45RB isoform of CD45.
| Institute |
|---|
| Yale University |
| Cat. #: | 155241 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | FACS ; IF ; IP ; WB |
| Target: | CD45 |
| Reactivity: | Mouse |
| Host: | Rat |
| Class: | Monoclonal |
| Alternate name: | YCD45R-1 |
|---|---|
| Product description: | Monoclonal antibody directed against CD45RB isoform of CD45. Background and Research Application CD45RB is an isoform of CD45 with exon 5 splicing (encodes B determinant). It is a 220 kD glycoprotein expressed on peripheral B cells, na?ve T cells, thymocytes, weakly on macrophages, and dendritic cells. CD45 regulates Src-family kinases, integrin-mediated signal transduction pathways and can suppress JAK kinases, acting as a negative regulator of cytokine receptor signalling. It plays a criti… |
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Molecular weight: | 190 kDa and 220 kDa |
| Immunogen: | cloned T cell lines belonging to the helper T cell (Th2) subset, final boost was given with helper/Th2 clone D10 |
| Immunogen Uniprot ID: | P08575 |
| Target background: | Monoclonal antibody directed against CD45RB isoform of CD45. Background and Research Application CD45RB is an isoform of CD45 with exon 5 splicing (encodes B determinant). It is a 220 kD glycoprotein expressed on peripheral B cells, nave T cells, thymocytes, weakly on macrophages, and dendritic cells. CD45 regulates Src-family kinases, integrin-mediated signal transduction pathways and can suppress JAK kinases, acting as a negative regulator of cytokine receptor signalling. It plays a cr… |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Shao et al. 2020. J Immunol. 204(1):37-48. PMID: 31757864. Garo et al. 2019. Cell Rep. 28(13):3353-3366.e5. PMID: 31553906. Timilshina et al. 2019. Cell Rep. 27(10):2948-2961.e7. PMID: 31167140. Imbratta et al. 2019. Sci Rep. 9(1):6135. PMID: 30992496. Lyons et al. 2018. PLoS Biol. 16(3):e2002417. PMID: 29596476. Lyons et al. 2018. Sci Signal. 11(519):. PMID: 29487189. Bottomly et al. 1989. Eur J Immunol. 19(4):617-23. PMID: 2567241. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.